Biocuration

EQS-News: Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

Retrieved on: 
Monday, September 25, 2023
CSE, CURE, Infection, RNA, Doctor of Philosophy, Advisory board, Patient, Transaction, Letter, Therapy, Biocuration, Security (finance), Commercial property, Pharmaceutical industry

Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction.

Key Points: 
  • Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction.
  • Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder.
  • Tübingen/Martinsried, Germany – September 18, 2023 – Atriva Therapeutics GmbH (“Atriva”) is pleased to disclose the signing of an exclusive letter agreement, dated September 14, 2023, with Biocure Technology Inc. (“CURE”) (CSE: CURE), based in Vancouver, Canada.
  • “This letter agreement underscores our commitment to leverage this transaction with CURE as an attractive growth option for Atriva and its stakeholders.

Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

Retrieved on: 
Monday, September 18, 2023
CSE, CURE, Infection, RNA, Doctor of Philosophy, Advisory board, Patient, Transaction, Letter, Therapy, Biocuration, Security (finance), Commercial property, Pharmaceutical industry

Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction.

Key Points: 
  • Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction.
  • TÜBINGEN, Germany and MUNICH, Germany, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atriva Therapeutics GmbH (“Atriva”) is pleased to disclose the signing of an exclusive letter agreement, dated September 14, 2023, with Biocure Technology Inc. (“CURE”) (CSE: CURE), based in Vancouver, Canada.
  • “We are delighted to have entered into this exclusive letter agreement with Biocure.
  • “This letter agreement underscores our commitment to leverage this transaction with CURE as an attractive growth option for Atriva and its stakeholders.

Orderinbox Launches Its Game-Changing Social NFT Marketplace For the Metaverse

Retrieved on: 
Tuesday, May 10, 2022
Ethereum, Comment, Multilingualism, ETH, DAI, USDC, NFT, Music, Community, Intellectual, Sale, Language, Non-fungible token, Technology, Ownership, Sport, Biocuration, MetaMask, Social media, Multimedia, Video game, Creative industries, Public relations, Online shopping, Cryptocurrency, Polygon, BC, Metaverse

VANCOUVER, BC, May 10, 2022 /PRNewswire/ - Today, Orderinbox , the social NFT marketplace for the metaverse has officially launched to the public.

Key Points: 
  • VANCOUVER, BC, May 10, 2022 /PRNewswire/ - Today, Orderinbox , the social NFT marketplace for the metaverse has officially launched to the public.
  • The platform displays a community curated marketplace and a personalized yet unbiased, chronological social feed that provides visibility to all users.
  • Social Feed: Social profiles with buzzing feeds include marketplace activity and engagement features like follow, like, share, and comment.
  • 1-Click NFT Creation: Minting an NFT is as easy as creating a social media post.

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Notice of Allowance for the Company’s United States Patent Claims on Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy

Retrieved on: 
Tuesday, March 29, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Company, Drug development, Cancer, Survivor, United States Patent and Trademark Office, LinkedIn, Human, Sale, Lung, Patent, Neck, Malnutrition, Investigational New Drug, Forward-looking statement, Board, Skin, Nanoparticle, Breast, Solomon Airlines, Head, Tissue, Xerostomia, Prevalence, Drug discovery, Biocuration, Twitter, Prostate cancer, The Company, COVID-19, Physician, News, Edwards Lifesciences, Saliva, Nature, Instagram, Lung cancer, Patient, Radiation, Medical imaging, Facebook

This new patent builds upon the 8 US patents BioCurity exclusively controls related to its novel drug development.

Key Points: 
  • This new patent builds upon the 8 US patents BioCurity exclusively controls related to its novel drug development.
  • Globally, it is estimated that 6 million of the 18 million annually diagnosed new cancer patients receive radiation.
  • BioCurity is a preclinical biotech company with a mission to prevent certain short term and long-term side effects of radiation therapy for cancer patients undergoing radiation therapy.
  • Burning and blistering and permanent scarring of the skin can also result for cancer patients undergoing radiation therapy.

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects

Retrieved on: 
Thursday, March 10, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Central Florida, The Company, Twitter, University, Drug development, Physician, Company, Burns, Instagram, Solomon Airlines, Cancer, MD Anderson Cancer Center, Health, Biocuration, Nature, Board, News, Chief Medical Advisor to the President, Nanoparticle, Skin, Sale, Radiation, Doctor of Philosophy, Patient, COVID-19, Survivor, Edwards Lifesciences, Forward-looking statement, LinkedIn, Patent, Medical imaging, Pharmaceutical industry, Facebook

BioCurity, is a preclinical biotech company developing drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.

Key Points: 
  • BioCurity, is a preclinical biotech company developing drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.
  • BioCurity offers the potential to prevent the often-devastating side effects associated with radiation therapy and to enhance the treatment outcomes for patients.
  • BioCurity is a global leader in drug development using cerium oxide nanoparticles to mitigate the side effects associated with radiation therapy.
  • BioCurity is biotech company with a mission to prevent certain short term and long-term side effects of radiation therapy for cancer patients undergoing radiation therapy.

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation at ACRO Summit 2022 on Sensitizing Head and Neck Cancer to Radiation Using the Company’s Cerium Oxide Nanoparticles

Retrieved on: 
Thursday, March 10, 2022
Technology, Research, Nanotechnology, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, Head, Lung, The Company, Mucositis, Twitter, Hydrogen peroxide, Reactive oxygen species, Company, Breast, Prostate, Colorectal cancer, Radiation, FDA, Cell, Instagram, Cancer, American College, Biocuration, Radiation therapy, Nature, Board, News, DNA, Nanoparticle, ROS, Toxicity, Neck, Doctor of Philosophy, Patient, Breast cancer, Sale, COVID-19, Administration, Forward-looking statement, LinkedIn, Medical imaging, Facebook, Cerium Oxide Nanoparticles, BioCurity, CERIUM OXIDE NANOPARTICLES, BIOCURITY

BioCuritys discovery could have a material positive impact for the millions of cancer patients that undergo radiation therapy annually.

Key Points: 
  • BioCuritys discovery could have a material positive impact for the millions of cancer patients that undergo radiation therapy annually.
  • Approximately 70% of head and neck cancer patients treated with radiation therapy will develop severe oral mucositis, limiting their ability to eat or drink.
  • Administration of cerium oxide nanoparticles at 1,000 times the effective dose did not produce toxicity in a small animal model.
  • BioCurity Pharmaceuticals Inc. is a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide.

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation of Data on Cerium Oxide Nanoparticles to Sensitize Radiation for Head and Neck Cancer at ACRO 2022 Summit

Retrieved on: 
Wednesday, January 12, 2022
Technology, Medical Devices, General Health, Science, Medical Supplies, Biotechnology, Health, Publishing, Public Relations, Investor Relations, Other Science, Research, Other Technology, Nanotechnology, Communications, Other Health, Pharmaceutical, Oncology, Nanoparticle, Forward-looking statement, Nature, Lung, Patient, News, LinkedIn, Prostate, COVID-19, The Company, Colorectal cancer, Reactive oxygen species, ROS, Poster, Radiation, DNA, Biocuration, Instagram, Company, Hydrogen peroxide, Head, Neck, Radiation therapy, Sale, Toxicity, Cancer, American College, Twitter, FDA, Cell, Breast, Administration, Medical imaging, Facebook, Cerium Oxide Nanoparticles, BioCurity, CERIUM OXIDE NANOPARTICLES, BIOCURITY

The agenda for the ACRO 2022 Summit can be found here , with the poster presentations scheduled for March 11, 2022, from 12:00 1:00pm EST.

Key Points: 
  • The agenda for the ACRO 2022 Summit can be found here , with the poster presentations scheduled for March 11, 2022, from 12:00 1:00pm EST.
  • BioCuritys cerium oxide nanoparticles possess fast catalase activity in a normal tissues neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue.
  • BioCuritys extensive preclinical studies in models of head and neck, lung, breast, pancreatic, prostate, and colorectal cancer show cerium oxide nanoparticles are regenerative and are not consumed in the reaction.
  • Administration of cerium oxide nanoparticles at 1,000 times the effective dose did not produce toxicity in a small animal model.

Former Novartis Executive Dr. Marie Lindner Joins Orthogon Therapeutics’ Board of Directors

Retrieved on: 
Monday, November 15, 2021
Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, Biocuration, BK, Therapy, Novartis, Arbutus Biopharma, Infection, Growth, Shire (pharmaceutical company), BK virus, Strategic partnership, Company, Ness Ziona, Drug discovery, Pharma, Internal medicine, Patient, Drug development, Pharmaceutical industry

Orthogon Therapeutics LLC, a drug development company focused on designing innovative antivirals and anti-infective therapeutics, announced that it has appointed Dr. Marie Lindner as an independent director to its board of directors.

Key Points: 
  • Orthogon Therapeutics LLC, a drug development company focused on designing innovative antivirals and anti-infective therapeutics, announced that it has appointed Dr. Marie Lindner as an independent director to its board of directors.
  • Prior to a BioPharma career that spanned over 30 years, Dr. Marie Lindner was board certified in internal medicine and clinical nutrition.
  • Her extensive background in biotech and with global pharmaceutical firms sets to strengthen the Orthogon board of directors.
  • Orthogon Therapeutics is a privately held drug discovery and development company developing a portfolio of infectious disease assets, including antiviral therapeutics.

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

Retrieved on: 
Wednesday, September 22, 2021
GlaxoSmithKline, US-China Strategic Engagement, Biocuration, IDD, Therapy, Medical Research Council, Clinical pharmaceutical scientist, Senior advisor, Global Health, American Association, National Health, Decision-making, White House, Royal college, Association, Physician, Novo Nordisk, Faculty, Senior, Bill, Consultant, Hematology, Company, Science Council, Pharmacology, Royal College of Physicians, Global health, Technology, Reproducibility, Drug development, Drug discovery, Amgen, Clinical research, Industry, Society, GLOBE, Management, Pharmaceutical industry

The Company also appointed David Mitchell, Ph.D., as Senior Vice President of Strategic Engagement and added C. Glenn Begley M.D., Ph.D., and Colin Pillai, Ph.D., as Senior Scientific Advisors.

Key Points: 
  • The Company also appointed David Mitchell, Ph.D., as Senior Vice President of Strategic Engagement and added C. Glenn Begley M.D., Ph.D., and Colin Pillai, Ph.D., as Senior Scientific Advisors.
  • Modern drug development is a team sport, and with the new clinical science group and these appointments, Certara will further advance our strategic partnerships and help train talent in model-informed drug development, saidCraig R. Rayner, President, Integrated Drug Development at Certara.
  • At Certara, Dr. Marshall will be responsible for establishing and growing the clinical science group of senior level scientists and physicians, which will drive clinical and medical elements of Certaras consulting offerings to clients.
  • At Certara, Dr. Begley will contribute to translational medicine, a key clinical science capability.